{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:21:23Z","timestamp":1791685283520,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Amgen, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12325-024-02889-8","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T14:02:23Z","timestamp":1716818543000},"page":"2978-2990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03347279","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tara F.","family":"Carr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Brusselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey L.","family":"Chupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-704X","authenticated-orcid":false,"given":"Andrew W.","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-6881","authenticated-orcid":false,"given":"Jean-Pierre","family":"Llanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke K.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shradha","family":"Chandarana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-7336","authenticated-orcid":false,"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"issue":"4","key":"2889_CR1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/cea.13790","volume":"51","author":"M Chen","year":"2021","unstructured":"Chen M, Shepard K, Yang M, et al. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021;51(4):546\u201355.","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"2889_CR2","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1080\/03007995.2018.1505352","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Golam S, Myers J, et al. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075\u201388.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2889_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"issue":"3","key":"2889_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","volume":"201","author":"ER Bleecker","year":"2020","unstructured":"Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201(3):276\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2889_CR5","doi-asserted-by":"publisher","first-page":"9274","DOI":"10.1038\/s41598-020-66445-4","volume":"10","author":"Z Csoma","year":"2020","unstructured":"Csoma Z, G\u00e1l Z, G\u00e9zsi A, et al. Prevalence and characterization of severe asthma in Hungary. Sci Rep. 2020;10(1):9274.","journal-title":"Sci Rep"},{"issue":"1","key":"2889_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.anai.2015.10.027","volume":"116","author":"TN Tran","year":"2016","unstructured":"Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37\u201342.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"2889_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.18176\/jiaci.0871","volume":"34","author":"C Domingo","year":"2024","unstructured":"Domingo C, Sicras-Mainar A, Sicras-Navarro A, et al. Prevalence, T2-biomarkers and cost of severe asthma in the era of biologics: the BRAVO-1 study. J Investig Allergol Clin Immunol. 2024;34(2):97\u2013105. https:\/\/doi.org\/10.18176\/jiaci.0871.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"supplement_1","key":"2889_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1164\/ajrccm.164.supplement_1.2103024","volume":"164","author":"TA Platts-Mills","year":"2001","unstructured":"Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001;164(supplement_1):S1\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"2889_CR9","unstructured":"Genentech Inc. XOLAIR\u00ae (omalizumab) for injection, for subcutaneous use: highlights of prescribing information (revised August 2023). Available from https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf. Accessed 8 February 2023."},{"key":"2889_CR10","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention (2023 update). Available from www.ginasthma.org. Accessed 2 January 2024."},{"issue":"7","key":"2889_CR11","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1016\/j.jaip.2021.02.059","volume":"9","author":"E Denton","year":"2021","unstructured":"Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680\u201388 e7.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"1","key":"2889_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13655","volume":"33","author":"N Mallah","year":"2022","unstructured":"Mallah N, Turner JM, Gonz\u00e1lez-Barcala FJ, Takkouche B. Gastroesophageal reflux disease and asthma exacerbation: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2022;33(1): e13655.","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"2889_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","volume":"195","author":"LC Denlinger","year":"2017","unstructured":"Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017;195(3):302\u201313.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2889_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","volume":"132","author":"G Scelo","year":"2024","unstructured":"Scelo G, Torres-Duque CA, Maspero J, et al. Analysis of comorbidities and multimorbidity in adult patients in the international severe asthma registry. Ann Allergy Asthma Immunol. 2024;132(1):42\u201353.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"22","key":"2889_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003459","volume":"95","author":"X Su","year":"2016","unstructured":"Su X, Ren Y, Li M, et al. Prevalence of comorbidities in asthma and nonasthma patients: a meta-analysis. Medicine (Baltimore). 2016;95(22): e3459.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2889_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.21053\/ceo.2017.01606","volume":"11","author":"S-D Kim","year":"2018","unstructured":"Kim S-D, Cho K-S. Samter\u2019s triad: state of the art. Clin Exp Otorhinolaryngol. 2018;11(2):71\u201380.","journal-title":"Clin Exp Otorhinolaryngol"},{"issue":"3","key":"2889_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1586\/ers.11.34","volume":"5","author":"L-P Boulet","year":"2011","unstructured":"Boulet L-P, Boulay M-\u00c8. Asthma-related comorbidities. Expert Rev Respir Med. 2011;5(3):377\u201393.","journal-title":"Expert Rev Respir Med"},{"key":"2889_CR18","unstructured":"AstraZeneca. TEZSPIRE\u00ae (tezepelumab) injection, for subcutaneous use: highlights of prescribing information (revised February 2023). Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761224s001lbl.pdf. Accessed 7 November 2023."},{"key":"2889_CR19","unstructured":"AstraZeneca. TEZSPIRE\u00ae (tezepelumab) injection, for subcutaneous use: summary of product characteristics. Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tezspire-epar-product-information_en.pdf. Accessed November 7 2023."},{"key":"2889_CR20","unstructured":"Kemp A. Tezspire approved in Japan for the treatment of severe asthma. Available from https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/tezspire-approved-in-japan-for-severe-asthma.html. Accessed 18 January 2024."},{"issue":"22","key":"2889_CR21","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","volume":"370","author":"GM Gauvreau","year":"2014","unstructured":"Gauvreau GM, O\u2019Byrne PM, Boulet L-P, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102\u201310.","journal-title":"N Engl J Med"},{"issue":"8","key":"2889_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","volume":"24","author":"GM Gauvreau","year":"2020","unstructured":"Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777\u201392.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"2889_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","volume":"23","author":"R Ebina-Shibuya","year":"2023","unstructured":"Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023;23(1):24\u201337.","journal-title":"Nat Rev Immunol"},{"key":"2889_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/all.15986","author":"M Caminati","year":"2023","unstructured":"Caminati M, Buhl R, Corren J, et al. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2023. https:\/\/doi.org\/10.1111\/all.15986.","journal-title":"Allergy"},{"issue":"19","key":"2889_CR25","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"2889_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.anai.2023.08.015","volume":"131","author":"ID Pavord","year":"2023","unstructured":"Pavord ID, Hoyte FCL, Lindsley AW, et al. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR). Ann Allergy Asthma Immunol. 2023;131(5):587\u201397 e3.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"2889_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/cea.14256","volume":"53","author":"J Corren","year":"2023","unstructured":"Corren J, Ambrose CS, Griffiths JM, et al. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: results from the phase 3 NAVIGATOR study. Clin Exp Allergy. 2023;53(4):417\u201328.","journal-title":"Clin Exp Allergy"},{"key":"2889_CR28","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2147\/JAA.S413064","volume":"16","author":"TM Laidlaw","year":"2023","unstructured":"Laidlaw TM, Menzies-Gow A, Caveney S, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR. J Asthma Allergy. 2023;16:915\u201332.","journal-title":"J Asthma Allergy"},{"issue":"1","key":"2889_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","volume":"21","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow A, Colice G, Griffiths JM, et al. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21(1):266.","journal-title":"Respir Res"},{"key":"2889_CR30","unstructured":"Ponce M. Pulmonary function tests. StatPearls [Internet]: Treasure Island (FL): StatPearls Publishing; 2022."},{"key":"2889_CR31","unstructured":"Regeneron Pharmaceuticals. DUPIXENT\u00ae (dupilumab): summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed 19 January 2024."},{"issue":"1","key":"2889_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","volume":"208","author":"J Corren","year":"2023","unstructured":"Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13\u201324.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2889_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","volume":"11","author":"A Menzies-Gow","year":"2023","unstructured":"Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023;11(5):425\u201338.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"2889_CR34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","volume":"181","author":"WC Moore","year":"2010","unstructured":"Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2889_CR35","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.jaci.2016.08.048","volume":"139","author":"D Lefaudeux","year":"2017","unstructured":"Lefaudeux D, De Meulder B, Loza MJ, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2017;139(6):1797\u2013807.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02889-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02889-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02889-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T06:36:48Z","timestamp":1719556608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02889-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2889"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02889-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tara F. Carr has served in an advisory role or as a consultant for AstraZeneca, Genentech, GSK, Novartis and Regeneron Pharmaceuticals. Wendy C. Moore has received consultancy fees for participation in advisory boards from AstraZeneca, GSK, Regeneron Pharmaceuticals and Sanofi; her institution has received research support from AstraZeneca, Boehringer-Ingelheim, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals, Sanofi, Suzhou Pharmaceuticals, Teva Pharmaceuticals and the US National Heart, Lung, and Blood Institute\/US National Institutes of Health. Monica Kraft has received research support from the American Lung Association, AstraZeneca, Janssen, Sanofi, Synairgen and the US National Institutes of Health, with funds paid to the University of Arizona and Mount Sinai Health System; has received personal fees from AstraZeneca, Chiesi, Genentech, Kinaset and Sanofi; and is a cofounder and Chief Medical Officer for RaeSedo, Inc. Guy Brusselle has received fees for participation in advisory boards and\/or speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, MSD, Novartis and Sanofi. Mario Castro has received grants\/research support from ALA, AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Patient-Centered Outcomes Research Institute, Pulmatrix, Sanofi-Aventis, Shionogi, Theravance and the US National Institutes of Health; has received consulting fees\/honoraria from Allakos, Amgen, Arrowhead, AstraZeneca, Genentech, Merck, Novartis, OM Pharma, Regeneron Pharmaceuticals, Sanofi and Teva Pharmaceuticals; and has received royalties from Aer Therapeutics and Elsevier. Geoffrey L. Chupp has received speaker and consultancy fees from Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Novartis, Regeneron Pharmaceuticals, Sanofi-Genzyme and Teva Pharmaceuticals. Michael E. Wechsler is an employee of National Jewish Health and has received consultancy fees from AstraZeneca, Equillium, Genentech, GSK, Novartis, Regeneron Pharmaceuticals, resTORbio, Sanofi and Teva Pharmaceuticals. Gillian Hunter, Luke K. Burke, Shradha Chandarana and Christopher S. Ambrose are employees of AstraZeneca and may own stock or stock options in AstraZeneca. Andrew W. Lindsley and Jean-Pierre Llanos are employees of Amgen and own stock in Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines and applicable regulatory requirements. Approvals from the Copernicus Central Institutional Review Board (Cary, NC, USA) and local independent ethics committees were obtained, and all patients or their guardians provided written informed consent in accordance with local requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}